On October 4, Lixte Biotechnology Received A Counter-signed Termination Letter Dated September 29, 2023, Ending The Exclusive License Agreement Dated August 20, 2018, Between The Company And Moffitt As Of September 30, 2023
Portfolio Pulse from Charles Gross
Lixte Biotechnology received a termination letter on October 4, ending the exclusive license agreement dated August 20, 2018, between the company and Moffitt as of September 30, 2023.
October 05, 2023 | 10:13 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The termination of the exclusive license agreement between Lixte Biotechnology and Moffitt could potentially impact the company's operations and future plans.
The termination of the exclusive license agreement could potentially disrupt Lixte Biotechnology's operations and future plans. This could lead to a negative impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100